PDF to PNG Logo.png
MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
August 19, 2020 12:59 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta”) (NASDAQ GS: MNTA) regarding possible...
Aleafia Health - Science Seeding Wellness
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
July 24, 2020 07:15 ET | Aleafia Health Inc.
SPRAVATO® (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder Aleafia Health medical clinics along with select physicians and...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 21, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences logo
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
August 15, 2018 09:26 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences logo
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
July 30, 2018 07:55 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the William Blair 2018 Growth Stock Conference
June 01, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading specialty pharmaceutical company in the field of pain management and addiction...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
May 23, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences logo
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board
May 22, 2018 08:29 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 14, 2017 07:45 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO,...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...